Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2007 Oct;91(10):1259-60.
doi: 10.1136/bjo.2007.120303.

Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?

Silvia Bopp
Editorial

Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?

Silvia Bopp. Br J Ophthalmol. 2007 Oct.

Abstract

There has been dramatic progress in anti‐VEGF therapy, but future guidelines are needed

PubMed Disclaimer

Comment on

References

    1. Chakravarthy U, Adamis A P, Cunningham E T., Jr (VISION Clinical Trial Group). VEGF Inhibition Study in Ocular Neovascularization. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology 20061131508 - PubMed
    1. Rosenfeld P J, Brown D M, Heier J S, (MARINA Study Group) et al Ranibizumab for neovascular age‐related macular degeneration. N Engl J Med 20063551419–1431. - PubMed
    1. Brown D M, Kaiser P K, Michels M, (ANCHOR Study Group) et al Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. N Engl J Med 20063551432–1444. - PubMed
    1. Rosenfeld P J, Moshfeghi A A, Puliafio C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age‐related macular degeneration. Ophthalmic Surg Lasers Imaging 200536331–335. - PubMed
    1. Lux A, Llacer H, Heussen F M A.et al Non‐responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007911318–1322. - PMC - PubMed

MeSH terms